The FDA approved Vabysmo for the treatment of macular edema following retinal vein occlusion, according to a press release from Genentech.
“Retinal vein occlusion affects over 28 million people worldwide and over a million people in the U.S., so there is a massive area of unmet need,” Christopher Brittain, vice president and global head of ophthalmology product development at Genentech, told Healio. “For RVO patients specifically, [Vabysmo] met its primary endpoint, as we shared previously, providing this early and sustained improvement in visual acuity noninferior to the